Please note that during peak periods or due to stock availability, processing times may extend to 5-10 business days
Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date
The FDA and other policymakers should take immediate action to ensure the integrity of the FDA's rigorous regulatory review and approval process, the drug supply chain and decades of carefully balanced approaches to fostering innovation and generic competition. Eli Lilly, Novo Nordisks rival in the diabetes and obesity market, also is expected to launch a weight-loss pill, orforglipron, in the first half of this year
Monitor and measure what matters With the Nutrisense CGM Program, you can monitor your glucose with health tech like glucose biosensors and continuous glucose monitor (CGM)s, and analyze the trends over time with the Nutrisense App
Mounjaro (tirzepatide) is typically dosed weekly, not daily
Orforglipron, developed by Eli Lilly, is the first non-peptide oral GLP-1 agonist, achieving up to 1.8% HbA1c reduction and 1012% body-weight loss in Phase 3 trials
